TVARDI THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 0.00 shares.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 0.00 shares.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 2.01K shares.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 5.90K shares.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 26.53K shares.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 93.22K shares, a 92.97% increase from fiscal 2022.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 48.31K shares, a 64.68% decline from fiscal 2021.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 136.79K shares, a 144.91% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 0.00 shares 10-Q · filed 2026-08-14 | 7.91K shares derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-08 | |
| 2025-12-31 | 2.01K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | 26.53K shares 10-K · filed 2026-03-31 |
| 2025-09-30 | 5.90K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | 93.22K shares 10-K · filed 2024-03-06 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | |
| 2023-03-31 | 93.22K shares 10-Q · filed 2023-05-15 | |
| 2022-12-31 | 48.31K shares 10-K · filed 2023-03-06 | |
| 2021-12-31 | 136.79K shares 10-K · filed 2022-03-01 | |
| 2020-12-31 | 55.85K shares 10-K · filed 2021-02-25 | |
| 2019-12-31 | 555.85K shares 10-K · filed 2020-02-27 | |
| 2014-09-30 | 133.80K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |